Regenxbio Inc (RGNX)
7.40
+0.02
(+0.27%)
USD |
NASDAQ |
Dec 24, 16:00
Regenxbio Cash from Investing (Quarterly): 50.26M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Catalyst Pharmaceuticals Inc | -0.259M |
| Vertex Pharmaceuticals Inc | -348.00M |
| Sarepta Therapeutics Inc | -128.82M |
| Edgewise Therapeutics Inc | 25.36M |
| Entrada Therapeutics Inc | -82.93M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -40.55M |
| Cash from Financing (Quarterly) | -10.86M |
| Free Cash Flow | -184.74M |
| Free Cash Flow Per Share (Quarterly) | -0.8046 |
| Free Cash Flow to Equity (Quarterly) | -40.88M |
| Free Cash Flow Yield | -52.25% |